Ventripoint Enters Collaboration Agreement To Test Echocardiology Technology For Use With Canines

Ventripoint Diagnostics (TSXV: VPT) has entered into a new collaboration agreement as of this morning. The collaboration is with that of the Veterinary Hospital of North Carolina State University, where the company will work to test and evaluation the use of its VMS+ technology in echocardiography of canines.

The unique utilization of the firms echocardiology technology will then look to be expanded for use in all animals. If successful, the collaboration will enable the company to expand and diversify its product portfolio to provide advanced cardiac care for animals.

The technology is believed to enable a better initial assessment in canines than what is currently available for veterinarians on the market. Furthermore, the equipping and training of veterinarians on cardiac assessments using the firms tech would enable earlier detection and treatment of cardiac disease, which is critical to achieving a long-term outcome.

“Companion animals have heart problems, like their owners and so we are delighted to broaden our products to include veterinary services. Initial studies at NCSU have shown the VMS+3.0 can accurately reconstruct and measure the function of canine hearts and this more in-depth evaluation in collaboration with NCSU will verify the results.”

Dr. George Adams, Executive-Chairman of Ventripoint

Ventripoint Diagnostics last traded at $0.08 on the TSX Venture.


FULL DISCLOSURE: Ventripoint Diagnostics is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ventripoint Diagnostics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Gold Drilling Scaled to 60,000 Meters: How Big Can This Get? | Roger Rosmus – Goliath Resources

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

Ventripoint Diagnostics: Using AI To Analyze The Heart – The Daily Dive feat George Adams

Today on the Daily Dive, our host Cassandra Leah sits down with George Adams, Executive...

Wednesday, April 21, 2021, 01:30:00 PM

Ventripoint Diagnostics Tech To Be Used To Study Atrial Dysfunction In Children

Ventripoint Diagnostics (CSE: VPT) this morning announced the beginning of a new clinical study being...

Tuesday, February 23, 2021, 09:16:45 AM

Ventripoint: Uplisting To The OTCQB – The Daily Dive

Today on the Daily Dive, we are joined by George Adams, Chairman of Ventripoint Diagnostics...

Wednesday, January 19, 2022, 01:30:00 PM

Ventripoint Receives Further Funding From National Research Council of Canada

Ventripoint Diagnostics (TSXV: VPT) this morning had a brief release, indicating the firm has received...

Monday, December 6, 2021, 08:14:58 AM

George Adams: COVID-19 Damages The Heart – The Daily Dive

Today’s Daily Dive welcomes back Dr. George Adams, Executive Chairman of VentriPoint Diagnostics (TSXV: VPT)....

Friday, September 17, 2021, 01:30:00 PM